VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma
VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In high-risk newly diagnosed multiple myeloma (HRNDMM), two different induction regimens were evaluated for safety and efficacy: Bortezomib-Pomalidomide-Dexamethasone (VPd) and Bortezomib-Lenalidomide-Dexamethasone (VRd). Newly diagnosed high-risk MM patients(age > 18) were included in this retrospective study, who received VRd and VPd induction th...
Alternative Titles
Full title
VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4064660b89f54b7e866904af25ed4301
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4064660b89f54b7e866904af25ed4301
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-025-85398-0
